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Abstract:
PURPOSE: This study was designed to investigate the neuroprotective effects of a specific
nicotinic ACh agonist, PNU-282987, on the loss of retinal ganglion cells (RGCs) in a rat
glaucoma model. A time-dependent study using 2 mM PNU-282987 was performed to determine
the neuroprotective effect in the vertebrate retina.
METHODS: Hypertonic saline solution (2M NaCl) was injected into the episcleral vein of the
rat’s eye to reduce the numbers of RGCs and mimic the effect of glaucoma. In one set of
studies, PNU-282987 was applied to the right eye of each experimental animal as eye drops in
combination with the NaCl saline injections to determine if activation of nicotinic ACh receptors
has a neuroprotective effect in the vertebrate retina. In addition, PNU-282987 was tested by
itself without the hypertonic saline injection surgery, to investigate the physiological effect on
the RGCs.
RESULTS: The results from this study provided evidence that short-term treatment with PNU282987 before NaCl injection, provided neuroprotection against the loss of RGCs that is
normally associated with the procedure. Longer-term treatment resulted in a proliferation of
RGCs compared to their internal controls by an average of 28.97%. In addition, when PNU282987 was applied by itself without the NaCl injection to induce glaucoma-like conditions, it
caused a short-term decrease of RGCs, which was followed by proliferation of RGCs.

Four

weeks of PNU 282987 treatment induced an increase of RGCs by an average of 30.7%.
CONCLUSION: 2 mM PNU-282987 has direct effect on RGCs and was shown to prevent the
loss of RGCs normally associated with glaucoma-like conditions. It is possible that PNU282987 could be developed in the future as a treatment for the loss of RGCs that are associated
with a number of retinal diseases.

Introduction
The Anatomy and Physiology of the Eye
To understand how glaucoma affects the eye and vision, it is important to introduce the
basic structures and functions of the eye. The eye is a complex organ. It is the sensor that
gathers a significant amount of information about the environment that surrounds us (Kolb et al,
2007). The eyeball itself consists of three main layers; the outer layer contains the sclera and
the cornea, the middle layer is essential for providing the blood supply for the eye and includes
the iris and the pupil, and the inner layer is the retina. The sclera “the white of the eye” is the
protective outer layer of the eye, and the front portion of the sclera is called the cornea, which
allows the light to enter the eye. The cornea is a powerful refracting area that provides the eye’s
focusing power (Kolb et al, 2007). The choroid is the second layer of the eye that lies between
the sclera and the retina. It is the source that provides nourishment by blood vessels to the outer
layers of the retina. The pupil is the opening of the eye found in the center of the iris. The iris is
a muscular tissue and is the part of the eye that gives it color (Kolb et al, 2007). The retina is
the innermost layer in the eye. When rays of light enter the eye, they first travel through the
cornea, then through pupil light to fall onto the lens of the eye (Kolb et al, 2007). Next, the lens
focuses the rays of light, and then they are refracted onto the retina. Within the layers of the
retina, light impulses are changed into electrical signals (Sebastian, 2010). Then, these electrical
signals are sent through the optic nerve by the visual pathway to the occipital cortex at the
posterior of the brain. Finally, the brain interprets these electrical signals as a visual image.
Along with these three layers, there are additionally chambers of fluid that are: 1) the anterior
chamber between the cornea and iris, 2) the posterior chamber between the iris and lens, and 3)
the vitreous chamber, which is between the lens and the retina (Sebastian, 2010). The vitreous

chamber holds a thicker fluid called the vitreous humor, which provides the eye its shape
(Prasad, 2011).

There is also a clear watery substance that fills the anterior chamber of the eye

to help nourish the cornea and brings oxygen to the front tissue of the eye. This is called the
aqueous humor (Sebastian, 2010). It is significant to demonstrate the complexity of the eye
structure in order to understand glaucoma.
The Retina
The retina is a part of the central nervous system. The photoreceptors are receptive to
light (Sebastian, 2010). The photoreceptors lie in a layer against the back of the eyeball and is
one of several layers found in the retina. There are several layers that the vertebrate retina has.
These layers include: 1) inner limiting membrane, 2) nerve fiber layer, 3) ganglion cell layer,
which contains nuclei of ganglion cells and gives rise to optic nerve fibers, 4) inner plexiform
layer, 5) inner nuclear layer, 6) outer plexiform layer, 7) outer nuclear layer, 8) external limiting
membrane, 9) photoreceptors layer which includes rods and cones, 10) retinal pigment
epithelium (Prasad, 2011). The vision process begins in the photoreceptors of the retina when a
molecule of visual pigment that is highly specialized, called rod and cone photoreceptors,
absorbs a photon of light. This process is called phototransduction, which is the cellular
mechanism of light detection (Kefalov, 2011). Rods and cones share the same principles of
transduction; however, they have different physiologically function. For example, rods are so
sensitive that they can detect a single photon of light, which works perfectly for dim light vision
(Kefalov, 2011). On the other side, cones are less sensitive than rods; therefore, they cannot
signal in a dim light environment (Kefalov, 2011).

Figure 1:
This picture is clearly illustrated the several layers of the vertebrate retina.1
Retinal Ganglion Cells
The RGCs are the major emphasis of this study. Ganglion cells are the last output
neurons of the vertebrate retina (Kuehn, et al., 2005). The ganglion cell collects the electrical
signals that have been processed by the excitatory and inhibitory pathways within the retinal
complex network, and convert these electrical signals into spike trains. The optic nerve
accumulates all the axons of the ganglion cells, and then the spike travels along ganglion cell
axons to a higher visual center in the brain for sorting and integrating into advanced information
processing (Kuehn, et al., 2005). Retinal ganglion cells (RGCs) are the final sensory neurons in
the retina (Kuehn, et al., 2005). They are responsible for contrast detection and for visual acuity
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in the retina. These are the cells that are lost during the glaucoma process. Loss of the RGCs
leads to loss of vision and eventual blindness.
Neurotransmitters and Receptors in Retina
To understand the potential mechanisms of glaucoma, it is important to focus attention on
neurotransmitters in the retina. In the retina, there are several types of neurotransmitters and
receptors such as gamma aminobutyric acid, glycine, acetylcholine, serotonin, dopamine, and
glutamate (Marc, 2004). In this study, the focus will be on illustrating the release of glutamate
and acetylcholine neurotransmitters onto RGCs.

First, glutamate is the major excitatory and

common neurotransmitter in the retina (Connaughton, 2007).

In the vertebrate retina,

photoreceptors, bipolar cells, and most ganglion cells release glutamate neurotransmitter (Marc,
2004). Glutamate diffuses onto postsynaptic cells and binds to two different types of receptors.
The first type of postsynaptic receptor is called the metabotropic glutamate channel that activates
a second messenger cascade (Connaughton, 2007). The second type of postsynaptic receptor
opens an ionotropic channel and allows direct influx of sodium ions and calcium into cells
(Connaughton, 2007). Each receptor is characterized by its sensitivity to specific glutamate
analogues that is structurally similar to glutamate (Marc, 2004). Glutamate plays a significant
role to affect RGCs and is released from bipolar cells in the retina. Related studies have shown
that glutamate excites RGCs (Finlayson, 2010). Excitation of RGCs can occur by iontophoretic
application of glutamate and kainate, or through glutamatergic excitation of other cells such as
bipolar and amacrine cells (Finlayson, 2010).
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Acetylcholine (ACh) is classified as the fast excitatory neurotransmitter of the peripheral
nervous system (Marc, 2004). Acetylcholine is found in amacrine cells in the vertebrate retina
(Thompson, et al., 2006).

These acetylcholine containing amacrine cells have a unique

morphological and have been called starburst amacrine cells (Dmitrieva, 2007). There are two
types of acetylcholine receptors have been found in the mammalian retina on the RGCs, which
are muscarinic, that are grouped to heptahelical acetylcholine receptors, and nicotinic receptors,
which

include

ionotropic

acetylcholine

receptors

(Dmitrieva,

2007).

Related

electrophysiological studies have demonstrated that nicotinic acetylcholine receptors are found
on RGCs (Masland, 1976).
channels.

Nicotinic acetylcholine receptors are one type of ligand-gated ion

There are pentameric receptors that contain α2-α6 subunits and β2-β4 in α/β

combinations or homomeric forms that contain α7-α9 subunits (Dmitrieva, 2007). It has been
shown that subunit composition of nAChRs has agonist/antagonist affinity. α7 nAChRs are
categorized by their sensitivity to α-bungarotoxin (αBgt). Other molecular and pharmacological
studies of rat retina mentioned that both αBgt-sensitive and αBgt-insensitive nAChR subtypes
are affected in generating the light responses of some RGCs (Dmitrieva, 2007).
PNU-282987
PNU-282987 a novel highly selective agonist of the α7 nAChR, (N-[(3R)-1azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride) (Bodnar et al., 2005; Hajos et al.,
2005). The high specificity of PNU-282987 makes it a valuable agonist for addressing
neurodegenerative diseases such as glaucoma. PNU-282987 was initially developed by
Pharmacia and Upjohn to treat schizophrenia, but proved to be inappropriate for human use
because of its inhibition of hERG potassium channels located in the heart (Walker et al., 2006).
However, this agent may prove to be a promising future treatment for glaucoma if it is applied as

eye drops, but only if eye drop application does not reach the heart and affect cardiac physiology.
Previous studies from this lab using liquid chromatography and mass spectroscopy with triple
quad capabilities (LC/MSMS) demonstrated that PNU-282987 can be detected in the retina after
eye drops application but not in heart tissue (Mata, 2013).
In this study, 2 mM PNU-282987 was applied as eye drops in Long Evans rats in two
types of experiments. In one set of experiments, eye drops were applied with the surgery to
induce glaucoma. In another set of experiments PNU was applied as eye drop application by
itself. These experiments were done to determine if PNU-282987 helps prevent the loss of
RGCs. This agent may be used in future treatment for glaucoma if it is applied as an eye drops.
Glaucoma
Glaucoma is a degenerative retinal disease characterized by a loss of vision due to the
progressive loss of retinal ganglion cells RGCs that spontaneously causes damage to the optic
nerve (Glaucoma research foundation). The major risk factor associated with glaucoma is an
increase of intraocular pressure. However, elevated intraocular pressure (IOP) is not the only
damaging factor in glaucoma. The American Academy of Ophthalmology now defines
glaucoma as a group of diseases with certain features that damage the eye’s optic nerve and can
result in vision loss and blindness (Glaucoma research foundation). There are many different
types of glaucoma such as open-angle glaucoma, which is the most common form of glaucoma,
low-tension or normal-tension glaucoma, angle-closure glaucoma, congenital glaucoma,
secondary glaucoma’s, pigmentary glaucoma, and pseudoexfoliation glaucoma (Glaucoma
research foundation). In general, glaucoma commonly has no symptoms. It causes no pain, and
can develop in one or both eyes, which make it hard to notice it in early stages. According to

the World Health Organization, glaucoma is one of the leading causes of blindness in the world
and is the second leading cause of blindness after cataracts (World Health Organization). More
than 3 million Americans are living with glaucoma.

There is no cure for glaucoma yet, since

vision lost from the glaucoma disease cannot be restored. However, immediate treatment for the
early stages can delay the progression of glaucoma (Glaucoma research foundation).
In this study, glaucoma-like conditions were modeled in Long Evans rats and death of
RGCs was induced in order to determine if 2 mM PNU 281987 provided a neuroprotective effect
in preventing RGC loss in the vertebrate retina.
Mechanism of Apoptosis
Apoptosis is the process of programmed cell death (Reed, 2000) and has been shown to
be involved in glaucoma (Guo, et al,. 2005). Imperfections in apoptotic cell death regulations
could contribute to many diseases, including disorder of cell accumulation such as cancer, or cell
loss associated with neurodegeneration (Kuehn, et al,. 2005). The mechanism of apoptosis
involves a series of diverse regulators known as caspases (Kuehn, et al,. 2005). There are inputs
from signal transduction pathways into the core of cell death machinery, which is influenced by
the environmental stimuli to cause either cell death responses or survival maintenance (Kuehn, et
al,. 2005). However, when apoptosis process occurs in RGCs, the cell will shrink, causing
plasma membrane blebbing, and nuclear DNA cleavage by endonucleases known as caspases
(Reed, 2000).

Figure 2:
Diagram illustrating the mechanism of apoptosis process in a general cell.2
2

Materials and Methods
Animal model
Adult male and female Long Evan rats, between 3-month-old and 6-month-old rats, were
used in the study. Rats were housed in Western Michigan University. All procedures were
approved and all animals were cared for in accordance with the Institutional Animal Care and
Use Committee (IACUC) of Western Michigan University.
Surgery to Induce Glaucoma
Rats underwent a procedure to induce glaucoma-like conditions. Intraperitoneal
injection of 1.0 ml/kg KAX, containing of 5 ml of ketamine (100 mg/ml), 2.5 ml xylazine
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(20mg/ml), 1 ml acepromazine (10 mg/ml), and 0.5 ml sterile water, were used to anesthetized
Long Evans rats. Figure 3 illustrates the procedure of the injection. On the ventral side of the
rats, KAX was injected intraperitoneally, and the rat was observed until no reflexes were
detected. Their feet and tails were pinched and pulled to exam for any reflex action and to
confirm that rat was fully anesthetized. Then, two drops of 0.5% procaine hydrochloride, a
topical anesthetic, was applied to the right rat eye in each experimental rat before the surgery to
induce glaucoma. A hemostat was used to pinch the eyelid and the tissue around the right eye to
bulge the eye out of the eye socket, in order to view the episcleral vein. Under the microscope,
the episcleral vein of the right eye was injected with 50 µl of sterile 2 M hypertonic saline
containing NaCl, while the left eye was left untreated for each experiment and was provided as
an internal control for each experiment. The micro needle that was used for the NaCl injection
was made of glass and was pulled from a Narishige electrode puller, and inserted into a 23 gauge
needle with the tip filed off. The tip of the pulled glass injector was beveled to a sharp point that
made it easy to penetrate into the episcleral veins. When 50 µl of sterile 2 M hypertonic saline
was injected into the episcleral vein, it caused a blanching inside the vein that indicated
successful injection. Previous studies have demonstrated that blanching of the episcleral veins
led to significant loss of retinal ganglion cells within 1 month following the injection (Iwamoto
et al., 2013). Injection of the hypertonic saline causes scaring in the trabecular meshwork,
decrease aqueous outflow and leads to a gradual increase in intraocular pressure (IOP), which is
the primary risk factor associated with glaucoma (Morrison et al., 1997). Following the
injection, the hemostat ring was detached and a small amount of polysporin ophthalmic ointment
(antibiotic cream) was applied over the crimped site of the right eye. The entire procedure was

completed before the animal woke from it’s anesthetic. The animal was returned to the cage and
was closely watched until the animal fully recovered before being returned to the animal facility.

Figure 3:
Schematic representation of hypertonic saline injection to induced glaucoma.
Eye Drop Application
To address the issue that the specific α7 nicotinic agonist, PNU-282987 can significantly
reduce the loss of RGCs accompanying glaucoma, PNU eye drops at 2 mM concentration was
used to determine 1) RGC with minimum treatment, 2) RGC survival after 4 weeks of PNU
treatment, after 3 weeks of PNU treatment, after 2 weeks, after 1 week and 3) RGC survival after
1-3 days of PNU treatment and finally if 4) RGC survival after 1 eye drops of PNU.

In one set

of experiments, 2 mM PNU was applied before and after NaCl injection to induce glaucoma-like
conditions (Table 1). In other experiments, PNU was applied by itself without the procedure to
induce glaucoma (Table 1). Animals were sacrificed one month following the beginning of any
PNU treatments.

Experiments

PNU-282987 treatment

The procedure to inject
hypertonic saline

A)
1 day

Yes

No

3 days

Yes

No

3 weeks

Yes

No

4 weeks

Yes

No

1 drop

Yes

Yes

1 day

Yes

Yes

3 days

Yes

Yes

1 week

Yes

Yes

2 weeks

Yes

Yes

4 weeks

Yes

Yes

No

Yes

B)

C)
Just the surgery to induce
glaucoma-like conditions

Table 1:
Summary of the experiments performed.

Eye drops were used to apply 2 mM PNU directly to the eye. Eye drops were applied
twice a day for the determined period of time. Eye drops were delivered twice a day since
previous studies have demonstrated that PNU-282987 was detected in the retina up to 12 hours
after application (Linn, et al,. 2013). The PNU eye drops were applied to the right eyes of all
experimental rats, while the left eye was left untreated. Eye drops were applied while the rats
remained in their cages. Cheerios were given to the rats as a positive reinforcement. One drop

twice a day for each rat’s right eyes were applied by using separate plastic disposable pipettes
which provided easy access for the eye through the cage bars. One month following the PNU
treatment, rats were sacrificed and retinas were stained with an antibody against Thy 1.1 to label
the Thy 1.1 glycoprotein found only on RGCs in the retina (Barnstable and Drager, 1984).

Removal and processing of Retina
After rats were exposed to 2 mM PNU-282987 for their assigned amount of time, rats
were euthanized using carbon dioxide asphyxiation for 5 minutes. The rat was checked after the
5 minutes to assure if there was no respiratory or reflex activity. Both the right and left rat
eyeballs were removed from the head, and placed into phosphate buffered saline solution.
Retinas were surgically removed from both left and right eyes by manual removing the cornea,
iris, lens, and vitreous humor, in order to separate them from the retina. Then, the whole retina
was able to be peeled out from the back of the remaining eyecup. We carefully removed the
retinas under the microscope so the retinas would remain in one piece after cutting the optic
nerve. The whole retinas were then flat mounted after four evenly spaced slits were made
around the periphery of the retina. Then, all retinas were pinned out in a sylgard dish with the
RGC layer facing upward using cactus needles, and fixed in 10% formalin overnight at 4º C.
Figure 4 shows an example of a flat mounted retina.
The following day, the retinas were rinsed with PBS, incubated in 2% BSA in PBS
containing 0.02% saponin for 30 minutes at room temperature to block non-specific binding,
then incubated in mouse anti-rat monoclonal antibody against Thy 1.1 (1:300; Millipore,
Billerica, MA) for 1 week at 40C in PBS containing 0.02% saponin. After a week, the retinas
were rinsed three times with PBS, and then incubated in Alexa Fluor 595 (Life Technologies,
Grand Island, NY) secondary goat anti-mouse antibody (1:300) for 5 days at 40C for
visualization.
In control studies, experiments were conducted to display specificity of the antibodies
used. In some negative control experiments, large RGCs were processed with the primary
antibody omitted, while other experiments substituted non-immune mouse immunoglobulin
(dilution: 0.1 – 1.0 µg/ml) for the monoclonal antibody. In other experiments, preabsorption

controls were performed where the primary antibody and Thy 1.1 antigen were added together
before applying to tissue. No significant epifluorescence was observed under any of these
conditions.

Optic
Nerve
Head

2 mm
Figure 4: Flat mount of a rat retina.
The yellow squares indicate the region of the retina were RGC counts where obtained.
Confocal Microscopy and Analysis
Once stained, the incubated tissues was rinsed and mounted on glass slides using 50%
PBS and 50% glycerol. Under a Zeiss confocal microscope, the retinal tissue in the glass slides
was imaged. Using the Z stack capabilities of the microscope, images were obtained throughout
the entire ganglion cell layer at 2 micron increments. The RGCs distribution is uneven in
different regions of the rat retina, therefore the images was obtained from regions that

surrounded the optic nerve head 4 mm away from the of the optic nerve. Previous studies from
this lab have demonstrated that the greatest amount of damage and loss of RGCs occurred 4 mm
from the optic nerve head (Iwamoto et al., 2013).
The total numbers of the labeled RGCs in these regions around the optic nerve head were
counted in the experimental retinas and control retina using Adobe Photoshop software. 4
images were taken from each retina and RGC counts were averaged in all cases. Finally, the
areas counted in the both retinas the right experimental and the left control were compared and
contrasted in each rat case.
Data Analysis
All cell counts were compared to the internal control counts for each experiment.
Student T-tests were used for single comparisons. A p-value of < 0.05 represents significance.
Graphs were plotted with Excel software.

Results
Inducing Glaucoma-like conditions
In this study, three different experiments were performed to investigate RGC survival in
the Long Evans rat retina. The first experiments injected hypertonic saline into the right eyes of
Long Evans rats to induce glaucoma-like conditions with no treatment of the alpha7 nAChR
agonist, PNU-282987. The left eye acted as an internal control for each experiment. The second
set of experiments only added 2mM PNU as eye drops without the NaCl injection to induce
glaucoma-like conditions. Finally, the third set of experiments injected hypertonic saline into the
episcleral veins while treating the right eyes of Long Evans rats with 2 mM PNU-282987.

The effect of hypertonic injections
In each experimental animal, the left eye was left untreated to act as an internal control
and the right experimental eyes were injected with hypertonic injections to induce glaucoma-like
conditions. One month following injection of the hypertonic saline into the episcleral vein of the

right eye, animals were sacrificed, the retinas were removed in one piece, flat-mounted onto
sylgard dishes and the retinas were processed for visualization using an antibody against Thy 1.1
to label RGCs. Figure 5 is an example of the results that obtained following this procedure.
Figure 5A demonstrates an image of labeled RGC axon fascicles and labeled RGCs that was
obtained from the left control untreated eye of a Long Evans rat 4 mm from the ONH. Figure 5B
demonstrated an image of labeled RGCs and labeled RGC axon fascicles from a similar retinal
location, from the right eye of the same rat, which underwent NaCl injections into the episcleral
veins to generate glaucoma-like conditions. One month after the right eye was injected with
hypertonic saline, there was noticeable and significant decrease of RGCs compared to the
internal control. RGC counts in the injected eye decreased by 26.83% (±5.2) and represented a
significant difference from the internal control condition.

Left Eye (Control)
A

BRight Eye (Experimental))

A

B

100 µm
Figure 5: Arrowheads indicate labeled RGCs and the double arrow indicates axon fascicles.
(A) Left control eye: with labeled RGCs using antibody against Thy 1.1 in gray scale. (B) Right
eye: one month following injection of 50µl hypertonic saline. Both images were taken from the
same animal and from the same region of the retina.

To summarize the effects of hypertonic injections on RGCs loss compared to control
untreated conditions, the bar graph in figure 6 shows the effect of inducing glaucoma-like
conditions with 2M hypertonic saline injections compared to the control eye. The light gray bar
represents the average percent change of RGCs from control untreated conditions. When eyes

were injected with NaCl, the percent of RGCs decreased by an average of 26.83 % after 1 month
(±5.2; N=6). This represents a significant difference from untreated controls.

Total % RGCs

100

*

80
60
40
20
0
Control

NaCl
Injection

Figure 6: This bar graph shows the percent of RGCs survival under control untreated conditions
and after NaCl injection into the episcleral veins. RGC percentage was analyzed one month
following the procedure to induce glaucoma-like conditions. The black bar represents the left
internal controls. The gray bar is the result obtained after hypertonic saline injection to the
episcleral vein and it shows a significant decrease in RGC compared to internal controls. Error
bars represent SEM. *Represents significance from control.

As described in the materials and methods, in some experiments, PNU-282987 was added
to the right eye as eye drops in each experimental rat before and after NaCl injections in order to
determine if PNU-282987 had any neuroprotective effects against the loss of RGCs that typically
occurs with the hypertonic treatment.
Previous studies have summarized the dose-dependent effect of eye drop application of
PNU-282987 one month after hypertonic injection into the episcleral veins. Eye drops were
applied two times each day for 3 days before the procedure to induce glaucoma-like conditions
and for one month following the procedure until the animal was sacrificed. Figure 7 illustrates
the effect of each dose of PNU-282987 on the percent of RGC survival. As seen in figure 7,
application of 100 μM PNU-282987 had no significant neuroprotective effect on RGC loss.
However, when 500 μM PNU-282987 was applied, significantly different results were found as
only 8.5 % of RGCs were lost compared to the near 27% typically lost with the hypertonic saline

injection. When 1mM PNU-282987 was applied, only 6.9% of RGCs were lost compared to
untreated control. Interestingly, when 2 mM PNU-282987 was applied to the right treated eye a
significant prevention of RGCS loss occurred and the RGC percentage actually increased by an
average of 10% compared to the untreated control. This proliferative effect was also observed
when 10 mM PNU-282987 eye drops were applied to the right treated eye, as RGC percentage
increased by an average of 11.5% compared to the untreated control. Therefore, 2 mM PNU282987 was the minimum dose that shows prevention of RGC loss as well as an increase of
RGCs. As a result, 2 mM PNU-282987 was the concentration of PNU used in this study.

Figure 7: Summary of results following eye drop treatment of PNU-282987. Each bar graph
represents the average change of RGCs compared to control untreated conditions. Treatment of
100µM PNU-282987, 500 µM PNU-282987, 1 mM PNU-282987, 2mM PNU-282987, and 10
mM PNU-282987 was applied for a month following the procedure to induce glaucoma-like
conditions. Eye drop application of PNU-282987 resulted in important prevention of RGC loss
in a dose dependent manner. (Mata, 2012)
* Represents significant different from the glaucoma-induced results (orange bar).

PNU treatment with no hypertonic injection
In another set of experiments, 2 mM PNU-282987 was applied as eye drops without
NaCl injections to induce glaucoma-like conditions to determine if PNU by itself could cause
RGC proliferation.

To find out the minimum treatment that may cause cell proliferation, 4

weeks PNU-282987 treatment, 3 weeks PNU-282987 treatment, 3 day PNU-282987 treatment,
and 1 day PNU-282987 treatment were tested. As illustrated in figure 8, image (A) represents
the left untreated internal control retina with labeled RGCs. Image (B) in figure 8, is the right
manipulating eye that was treated with just PNU for one day. There is a noticeable decrease of
RGCs. The one day treatment of 2 mM PNU-282987 produced a significant decrease in RGC
survival by 9.67% (±1.83) compared to the internal untreated control (figure 10). This suggests
that 2 mM PNU-282987 caused a loss of RGCs by itself.
When PNU-282987 treatment was extended for 3 days, there was also a significant
decrease in RGC survival. Fig 8(C) illustrates a left control untreated eye, while image 8(D)
illustrates the right experimental eye that was treated with just PNU-282987 for 3 days. 2 mM
PNU-282987 decreased RGC survival by an average of 22.3% (±11.4) compared to control
untreated conditions (figure 10). Again, this suggests that 2 mM PNU-282987 caused a loss of
RGCs by itself.

Therefore, relatively short-term exposure of 2 mM PNU caused a decrease of

RGCs.
Interestingly, when 2 mM PNU-282987 was added for 3 weeks, it did not decrease RGC
survival, but rather increased RGC survival. In fact, the results suggest that proliferation of
RGCs occurred. Fig 9(E) represents an image of a control untreated left eye, while fig. 9(F)
illustrates the image obtained from the right experimental eye that was treated with PNU-282987
treatment for 3 weeks. As seen in figure 9 image (F), there is an obvious increase of RGCs.
After 3 weeks of PNU treatment there was an increase of RGCs by an average of 19.54% (±3.1)
(figure 10). This potential proliferation of RGCs was also seen if retinas were treated with
PNU-282987 for 4 weeks. Fig 9(G) illustrates a left untreated control eye, while image (H)
represents an image of the right experimental eye of the same rat that has been treated with PNU282987 for 4 weeks. As seen in figure 9, image (H) there were a significantly more number of
RGC in the right manipulated eye comparing to the left control eye image (G). In fact, the
experiment of PNU-282987 treatment for 4 weeks indicated that RGC survival increased by an

average of 30.7% (±10.82) (figure 10). Each dose of PNU- 282987 produced a different effect
on RGC survival and short term treatment had opposite effects of long term treatment.

Left Eye (Control)

A

BRight Eye (Experimental))
B

100 µm
Left Eye (Control)

C

C

Right Eye (Experimental))

D

100 µm
Figure 8: Illustration of the treatment of 2mM PNU-282987by itself. Image (A) was taken
from the left internal control eye, image (B) was taken from the right experimental eye that
treated by PNU treatment for 1 day, from the same rat and from the same retinal location.
Image (C) was taken from the left internal control eye, image (D) was taken from the right
experimental eye that was treated with PNU for 3 days. Arrow heads indicate labeled
RGCs and the double arrow indicates axon fascicles.

Left Eye (Control)

E

Right Eye (Experimental))
F\\\\\\\\\\\\\\\\\\\\\\\\F

F

100 µm
Left Eye (Control)

G

HRight Eye (Experimental))
H

100 µm
Figure 9: Illustration of the treatment of 2mM PNU-282987 by itself. Image 9 (E) was
taken from the left internal control eye, and image 9 (F) was taken from the right
experimental eye that was treated with PNU treatment for 3 weeks.
Image (G) was taken from the left internal control eye, and image (H) was taken from the
right experimental eye that was treated with PNU treatment for 4 weeks. Arrow heads
indicate labeled RGCs and the double arrow indicates axon fascicles.
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Figure 10:
Bar graph illustrating the average percent change in RGCs that occurred after PNU-282987 was
applied as eye drops for various amounts of time. N=between 3 and 6 for each time point. *All
results were significantly different from control untreated retinas.

Hypertonic injection with PNU treatment
In the next set of experiments, 2 mM PNU-282987 was applied before hypertonic saline
injections or PNU was applied before and after hypertonic saline injections. The following
experiments were performed: 1 drop of PNU-282987 an hour before NaCl injection, 1 day
treatment of PNU-282987 after NaCl injection, 3 days treatment of PNU-282987 followed by
NaCl injection, 1 week treatment of PNU-282987 followed by NaCl injection, 2 weeks
treatment of PNU-282987 followed by NaCl injection, and 4 weeks treatment of PNU-282987
followed by NaCl injection.
When one drop of PNU-282987 was added to experimental eyes before the NaCl
injections, there was significant neuroprotection against the loss of RGCs that is normally
associated with the hypertonic saline injections. As figure 11 illustrates, image 11(A) represents a
left untreated internal control retina with labeled RGCs using antibody against Thy1.1 in gray
scale. Image 11(B) is the right experimental eye that treated with one drop of PNU-282987 and the

hypertonic saline injected surgery. The two images have a similar number of RGCs. These results
are summarized in figure 14 and demonstrate that the average percent of RGCs decreased by 4.1%
(±4.2; N=3) with just one treatment of PNU-282987 before the hypertonic insult.
These same results were obtained when PNU-282987 eye drops were applied for 1 and 3
days before the hypertonic saline injection to induce glaucoma-like conditions. The images
comparing one day treatments and 3 day treatments are shown in figures 11 C and D and in figures
12 E and F respectively. For each treatment condition, the treated retinas contain similar number
of RGCs as their internal controls.

In figure 14, these results are summarized. 1 day of PNU

treatment before NaCl injection was associated with an average decrease of RGC survival by 6.7%
(±6.7; N=3). Three days of PNU treatment before NaCl injection was associated with an average
decrease of RGC survival by 6.3% (±3.1; N=3). These values are significantly different from the
percent of RGCs that survive if only NaCl injections were made and provide evidence that short
treatments of PNU-282987 provide neuroprotection against loss of RGCs.
Longer term treatments with PNU-282987 provided opposite results concerning RGC
survival. Figure 12G is an image of a left untreated control eye, while image 12H represents an
image from the right experimental eye that was manipulated with PNU-282987 treatment for 1
week following the hypertonic saline injected surgery. Unlike the results obtained with short term
application of PNU-282987, longer exposure does not provide significant neuroprotection against
loss of RGCs. In fig. 12H, there are fewer RGCs than in fig. 12G. RGCs cell decreased by an
average of 18.3% (±0.05; n=3) in the right experimental eye that was treated for 1 week of PNU
treatment after the hypertonic saline injection (fig. 14). The results obtained after the week
treatment were significantly different from the short term PNU treatments but not significantly
different from retinas that were only injected with hypertonic saline (no PNU treatment).
When 2 mM PNU-282987 was applied for a longer time, the results changed once again.
If PNU treatment occurred before and after NaCl injections for 2 and 4 weeks, proliferation of
RGCs occurred. This can be seen in figures 13I through 13L.

Figure 13I represents an image of

a left untreated control eye, and fig. 13J illustrates the right experimental eye that was manipulated
with PNU-282987 treatment for 2 weeks after the hypertonic saline injection. When treated for an
extended period of time, there was proliferation of RGCs compared to the internal controls. A two
week treatment of PNU-282987 after NaCl injections increased the average percent of RGCs by

28.97% (± 10.2; N=3) (fig. 14). Four weeks of PNU-282987 treatment also appeared to increase
the number of RGCs (fig. 13K and fig. 13L) by an average percent increase of 24.2% (±2.3; N=3)
(fig. 14).

Left Eye (Control)
A

BRight Eye (Experimental))

A

B

100 µm
Left Eye (Control)
C

DRight Eye (Experimental))

C

D

100 µm
Figure 11: Illustration of the effect of hypertonic injection and the PNU-282987 treatment.
Image (A) is the left untreated control eye. Image (B) shown the right experimental eye
that was manipulated with hypertonic saline injection after being treated with one drop of
PNU-282987. Image (C) represents the left untreated control eye from another rat, and
image (D) represents the right experimental eye from the same rat that was treated with
2mM PNU for 1 day before hypertonic saline injection.
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Figure 12: Illustration of the effect of hypertonic injection and the PNU-282987 treatment.
Image (E) is the left untreated control eye. Image (F) shown the right experimental eye
from the same rat that was treated with PNU-282987 for three days before hypertonic
saline injection.
Image (G) represents the left untreated control eye, and image (H) represents the right
experimental eye that was treated with PNU for 1 week following injection.
Arrow heads indicate labeled RGCs and the double arrow indicates axon fascicles.
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Figure 13: Illustration of the effect of hypertonic injection and the PNU-282987 treatment.
Image (I) is the left untreated control eye image. Image (J) shows the right experimental
eye that applied PNU-282987 for 2 weeks following the injection.
Image (K) represents the left untreated control eye, and image (L) shows the right
experimental eye that applied PNU-282987 for 4 weeks following the injection. Arrow
heads indicate labeled RGCs and the double arrow indicates axon fascicles.
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Figure 14
Bar graph illustrating the percent change in RGCs; calculated by comparing the left untreated
internal control eye to the right experimental eye. Results from fluorescent labeling experiments
were obtained after hypertonic saline injection and the treatment of PNU- 282987 under different
conditions. * Represents the results were significantly different from the results obtained with
just surgery.

Discussion
Many neurodegenerative diseases, such as glaucoma, have been connected with overstimulation of receptors resulting in cell death. Neuroprotection against over-stimulation of
receptors has been used as a therapeutic method to many neurodegenerative diseases. In this
study, the neuroprotective effect of 2 mM PNU-282987, α7 nAChR-specific agonist was
analyzed to determine if it could prevent loss of RGCs that caused by the glaucoma-inducing

procedure. Previous studies using various concentrations of PNU-282987 demonstrated a dosedependent response on RGC survival (Iwamoto et al., 2013; Mata, 2013). These results
demonstrated that 2 and 10 mM PNU-282987 not only prevented the loss of RGCs associated
with the procedure to induce glaucoma-like conditions, but resulted in more RGCs than the
internal control counts. As a result, in this study, only 2 mM PNU-282987 was used to analyze
this effect in more detail.
Results from this study provided evidence that PNU-282987, a specific nAChR agonist,
has a major effect in RGCs. After the surgery to induce glaucoma-like condition, a significant
loss of cells from the RGCs layers occurred. Previous studies have demonstrated that the
procedure to induce glaucoma increases intraocular pressure (IOP) by causing scaring of the
trabecular meshwork tissue (Morrison et al., 1997). This procedure significantly reduced RGCs
density by an average of 26.83% after 1 month. This procedure to induce glaucoma was used to
test the hypothesis that eye drop application of the α7 nAChR agonist, PNU-282987 can prevent
loss of RGCs in rat glaucoma model. The results demonstrated that short-term treatment (1drop
of PNU – 1week) of α7 nAChR agonist, PNU-282987 (2mM), provided some degree of
neuroprotection against RGC loss. Surprisingly, relatively long-term treatment (2 weeks- 4
weeks) with the α7 nAChR agonist, PNU-282987 (2 mM), demonstrated that proliferation of
RGCs occurred. 2 mM PNU-282987 not only prevented the loss of RGCs in the rat glaucoma
model but also actually resulted in significantly more RGCs compared to its internal control
when applied as eye drops over a relatively long period of time.

Previous in-vitro studies from this laboratory have clearly outlined the potential
mechanisms for neuroprotection against glutamate-induced cell death in the pig retina. ELISA
studies has illustrated that ACh activation of α7 nAChRs triggers phosphatidylinositol-3-kinase
(Pl 3) phosphorylates Akt to activate BCl2 (Asomugha et al,. 2010) and prevents cytochrome C
release from the mitochondria (Figure 15). Preventing cytochrome C release from the
mitochondria will inhibit caspase activation and the apoptotic process from being initiated, to
prevent loss of RGCs associated against glutamate-induced cell death (Asomugha et al,. 2010).
This neuroprotective effect of Pl3 can be tested in the in vivo model of glaucoma to determine if
the same survival pathway initiated in culture is also involved in glaucoma. Pl3 inhibitors could
be used before application of PNU-282976 to determine if the PI3 – akt pathway is involved in
PNU’s effect. The activation of this neuroprotective pathway was found to be initiated by Ca+2
influx throughout α7 nAChR channels in cultured cells (Brandt et al., 2010). It is likely these
neuroprotective pathways are also involved in the in vivo glaucoma model, but further studies
are required to test this hypothesis.
Ca+2 influx through glutamate-activated NMDA receptors has been shown to be the
major trigger for RGC death in glaucoma models that is facilitated through over-stimulation of
receptors (Brandt et al., 2010). Interestingly, Ca+2 influx through nAChRs is also involved in
initiating the neuroprotective pathways and preconditioned the cells against a subsequent larger
calcium ions influx due to glutamate-insults on cultured pig RGCs. This preconditioning dose of
calcium ions seems to be the key for neuroprotective effects in these models.
The apoptosis mechanism associated with glutamate-induced excitotoxicity was also
illustrated from previous in-vitro work from this laboratory. The overstimulation of glutamate
receptors in the pig retina lead to activate MAPKKK that activates MAPKK that activates p38

MAPK (Asomugha et al,. 2010),which will stimulate the release of cytochrome C from the
mitochondria, to trigger caspase activity and apoptosis (Figure 15). The cell death mechanism
associated with glaucoma in rat RGCs is still under investigation. ELISA and pharmacology
investigations must be performed in the glaucoma model to determine if p38 MAP kinase is
involved in RGC death in the rat model. Mechanisms can differ between different models, and
further studies are required to determine what pathways are involved in the death of RGCs
associated with the procedure to induce glaucoma.
When 2 mM PNU-282987 was applied for over 2 weeks, there was a significant increase
of RGCs compared to the internal control eyes. This occurred whether PNU 282987 was applied
by itself or if PNU 282987 was applied after the procedure to induce glaucoma. Therefore, it
was PNU itself that likely produced the proliferating effect. Although neuroprotection occurred
with lower concentrations of PNU-282987, the proliferation of cells was only seen if 2 and 10
mM PNU-282987 was used for a relatively long period of time. This response to 2 mM PNU is
very surprising as adult neurons do not typically divide or proliferate. The molecular factors
behind the increase of the RGCs due to high dose exposure of PNU-282987 for a relatively long
period of time is still unknown, but there are many possibilities; 1) this high dose of PNU282987 could cause mitotic division of previously undiscovered stem cells in the adult
mammalian retina. 2) 2 mM PNU-282987 could be causing a cancerous effect, or 3) the
antibody that selectively stains only RGCs could be labeling other type of cells. This
phenomenon of increased RGCs was an unexpected response. The cells remaining after long
term treatment with 2 mM PNU morphologically look like the normal RGCs, however, further
studies need to be conducted to determine if these cells are indeed new RGCs and if they are
functional. Mitotically active markers can be used in the future to label proliferating cells. This

procedure could be used to double label the RGCs in the retina after long-term exposure to PNU.
Understanding the mechanism of the neuroprotection or proliferation of RGCs caused by PNU282987 in the retina can eventually lead to the future therapies for glaucoma and other
neurodegenerative diseases of the CNS.

Figure 15: Scheme proposing
This proposed schematic of ACh-induced neuroprotection and apoptosis. It demonstrates the
activation of nAChRs triggers cell survival through activates: Pl3 kinase  Akt  BCl2, which
then prevents the release of cytochrome C, that inhibiting the apoptotic processes. On the other
side, it shows the apoptosis mechanism by the excitotoxic effect of excessive glutamate that
activates: MAPKKK  MAPKK  p38 MAPK, which leads to singling the release of
cytochrome C from the mitochondria that activates the apoptotic effect.

ACh is normally found in the vertebrate retina, and it is release from the starburst
amacrine cells onto RGCs. Studies have been illustrated that RGCs are the main target in cell
loss in glaucoma. As a result, there should be naturally occurring neuroprotection to the RGCs.
However, ACh release may be affected under glaucomatous conditions. Therefore, the normal
neuroprotective effect of ACh could be lost by glaucoma. If ACh does in fact provide
neuroprotection in normal physiological states, this effect may be enhanced with PNU-282987,
especially if ACh release from the starburst amacrine cells is compromised under glaucoma-like
conditions. The results of PNU-282987 in culture studies and in-vivo may lead to promising
effects in preventing nerve damage that is associated with experimental glaucoma models. In
conclusion, this study illustrates the potential of α7 nAChR agonists, including PNU-282987,
which is a different and unique way to treat glaucoma.
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